Polypeptides of Pseudomonas aeruginosa
AssigneeID Biomedical Corporation
InventorsNathalie Charland, Josee Hamel, Bernard Brodeur, Denis Martin, Isabelle Charlebois, Diane Bussiere
Life of this patent
Estimating the term…
Abstract
The present invention relates to polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and/or treat Pseudomonas aeruginosa infection.
Claims10
An isolated polypeptide consisting of the amino acid sequence set forth as SEQ ID NO:4 from which the signal peptide sequence set forth as SEQ ID NO:38 is deleted, wherein the polypeptide is capable of eliciting an immune response in a host to Pseudomonas aeruginosa.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an amount of a polypeptide that is capable of eliciting an immune response in a host to Pseudomonas aeruginosa, wherein the polypeptide consists of an amino acid sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO:4, and wherein the polypeptide is capable of inducing an antibody that binds specifically to a SPA-2 polypeptide consisting of the amino acid sequence set forth as SEQ ID NO:4.
A pharmaceutical composition comprising a polypeptide and a liposome, wherein the polypeptide consists of an amino acid sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO:4, and wherein the polypeptide is capable of eliciting an immune response in a host to Pseudomonas aeruginosa, and wherein the polypeptide is capable of inducing an antibody that binds specifically to a SPA-2 polypeptide consisting of the amino acid sequence set forth as SEQ ID NO:4.
A kit comprising a polypeptide for detection or diagnosis of Pseudomonas aeruginosa infection, wherein the polypeptide consists of the amino acid sequence set forth as SEQ ID NO:4 from which the signal peptide sequence set forth as SEQ ID NO:38 is deleted.
Dependencies are inferred from the claim text.